HC Wainwright Forecasts ALX Oncology FY2029 Earnings

ALX Oncology Holdings Inc. (NASDAQ:ALXO) – HC Wainwright issued their FY2029 earnings estimates for shares of ALX Oncology in a research report issued on Friday, January 24th. HC Wainwright analyst S. Ramakanth expects that the company will earn $0.63 per share for the year. HC Wainwright has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for ALX Oncology’s current full-year earnings is ($2.76) per share.

A number of other research analysts have also weighed in on the stock. Jefferies Financial Group lowered shares of ALX Oncology from a “buy” rating to a “hold” rating and dropped their price objective for the company from $12.00 to $2.00 in a research note on Thursday, December 19th. Cantor Fitzgerald restated an “overweight” rating on shares of ALX Oncology in a research report on Friday. Finally, UBS Group decreased their price target on shares of ALX Oncology from $4.00 to $2.20 and set a “buy” rating on the stock in a research note on Monday. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $3.05.

ALX Oncology Trading Up 2.6 %

NASDAQ:ALXO opened at $1.56 on Monday. The firm has a market cap of $82.01 million, a P/E ratio of -0.52 and a beta of 0.98. ALX Oncology has a 52 week low of $1.19 and a 52 week high of $17.83. The firm’s fifty day moving average is $1.62 and its 200-day moving average is $2.33. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82.

Insider Transactions at ALX Oncology

In other ALX Oncology news, Director Rekha Hemrajani bought 30,000 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was purchased at an average cost of $1.55 per share, with a total value of $46,500.00. Following the completion of the acquisition, the director now owns 33,000 shares in the company, valued at $51,150. This trade represents a 1,000.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 14,443 shares of company stock worth $23,309 in the last quarter. Company insiders own 33.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Hsbc Holdings PLC bought a new position in ALX Oncology in the second quarter worth about $63,000. AQR Capital Management LLC boosted its position in ALX Oncology by 50.7% in the 2nd quarter. AQR Capital Management LLC now owns 18,079 shares of the company’s stock worth $109,000 after purchasing an additional 6,080 shares in the last quarter. SG Americas Securities LLC raised its stake in shares of ALX Oncology by 33.6% during the 3rd quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock worth $50,000 after buying an additional 6,888 shares during the period. Algert Global LLC acquired a new position in shares of ALX Oncology during the 2nd quarter worth approximately $249,000. Finally, GSA Capital Partners LLP acquired a new position in shares of ALX Oncology during the 3rd quarter worth approximately $88,000. 97.97% of the stock is owned by hedge funds and other institutional investors.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.